As the first two programs targeting the helicase WRN enter the clinic for MSI+ cancers, they set up a comparison of different inhibitory mechanisms

With GV joining investor syndicate, the biotech’s ‘non-linear’ path will include HPK1 program rivaling Pfizer’s, as well as immunology and metabolic assets

BioCentury’s roundup of translational news

Bayer obtains Vividion’s platform to reach difficult-to-drug targets, plus preclinical pipeline

Artios and Merck KGaA’s deal marks the fourth time a large company partnered with a synthetic lethality-focused biotech this year, signaling continuing momentum for the tumor-targeting

GSK and Ideaya’s deal is the second in a month to move a pharma deeper into synthetic lethality